NCT02653599

A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 174 (actual)
• Sponsor: vTv Therapeutics · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is a multi-center, randomized, double-blind, placebo-controlled parallel group, Phase 2 study in subjects with Type 2 diabetes mellitus on a stable dose of metformin to evaluate the safety and efficacy of TTP273 versus placebo glucose control and body weight following administration for 3 months.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	TTP273
DRUG	Placebo

Timeline

• Start date: 2015-12-01
• Primary completion: 2016-11-01
• Completion: 2017-01-01
• First posted: 2016-01-12
• Last updated: 2017-02-10

Locations

30 sites across 1 country: United States

Regulatory

• FDA-regulated drug study